Sponsor content
34 result(s) found, displaying 11 to 20
-
Australian Public Assessment Report (AusPAR)Koselugo (selumetinib sulfate) has been approved for the treatment of paediatric patients 2 years of age and older with neurofibromatosis type 1 who have symptomatic, inoperable plexiform neurofibromas.
-
Australian Public Assessment Report (AusPAR)Ultomiris (ravulizumab) has been approved for the treatment of adult patients with Neuromyelitis Optica Spectrum Disorder who are anti-aquaporin 4 antibody-positive.
-
Prescription medicine registrationActive ingredients: ravulizumab.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for KOSELUGO selumetinib 25 mg capsule bottle.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for KOSELUGO selumetinib 10 mg capsule bottle.
-
Australian Public Assessment Report (AusPAR)AusPAR for Ultomiris (ravulizumab) for the treatment of paroxysmal nocturnal haemoglobinuria and atypical haemolytic uraemic syndrome
-
Prescription medicine registrationActive ingredients: ravulizumab.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for ULTOMIRIS ravulizumab rch 300 mg in 3 mL (100 mg/mL) concentrated solution for injection by intravenous infusion vial.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for ULTOMIRIS ravulizumab rch 1100 mg in 11 mL (100 mg/mL) concentrated solution for injection by intravenous infusion vial.
-
Prescription medicine registrationActive ingredients: ravulizumab.